ONCOTARGET: SPREADING MEDICAL KNOWLEDGE

Oncotarget is an online weekly medical journal. It offers freely accessible peer reviewed article relating to oncology, cell biology, neuroscience, cardiology, oncology, endocrinology and other sub disciplines of the biomedical field. The founders of Oncotarget are Mikhail Blagosklonny and Andrei Gudkov. They established it in 2010 with Impact Journals as its publisher. Oncotarget aims at spreading medical knowledge to reach more people, more rapidly. This was to fill in the gaps existing in the access and sharing of such knowledge. They realized that most online journals restrict their access which in return keeps most of the scientific discoveries unknown among people. Additionally, researchers have a hard time finding relevant knowledge during their researches which further impairs them.

Another limiting factor to scientific knowledge that Oncotarget recognized is mistaken rejection of scientific work but other journals. This not only discourages authors but also limits the amount of research papers done. Oncotarget therefore gives a second chance to papers that have been accidentally rejected. The authors of such papers are required to send the article, the peer-reviews received from the other journal and the rebuttal letter. It then analyses the rebuttal letter to assess the validity of the rejection. If invalid, the paper is reviewed again by the team at Oncotarget. Learn more about Oncotarget at Bioxbio.com.

Blagosklonny and Gudkov are the editors in chief of Oncotarget. They are also co-workers at the Roswell Park Cancer Institute in New York where Blagosklonny is a professor of oncology and Gudvok serves as the Senior Vice President for Basic research for the institution. They have worked together for a long time and are passionate about medical science. They are therefore a great team to lead Oncotarget.

Blagosklonny is interested in cancer research and has greatly engaged in it. He deals in development of innovative preventive measures, treatments and anti-cancer stratagem. He recently developed a hypothesis that argues that Target of Rapamycin (TOR) could have possible role in the aging process. The theory associates aging with the hyper functioning of the body cells. Blagosklonny has done numerous researches and has authored or co-authored over 250 peer-reviewed papers. He holds a MD in internal medicine and a PhD in cardiology from First Pavlov State Medical University of St. Peterburg. Follow Oncotarget journal on Twitter.